newsfilter
← Latest News
GlobeNewswire·

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

RYTM
  • Rhythm Pharmaceuticals appointed Manher "AJ" Joshi, M.D., as Chief Medical Officer effective August 17, 2026.
  • Dr. Joshi brings over two decades of experience in discovery, pivotal trials, regulatory processes, & life-cycle management from previous roles at Soleno Therapeutics, Neurona Therapeutics, & Atara Biotherapeutics.
  • Rhythm's lead asset, IMCIVREE (setmelanotide), is an MC4R agonist approved by the FDA & European Commission to treat obesity & hunger in patients with specific genetic deficiencies or acquired hypothalamic obesity.
  • The company is advancing a clinical pipeline including investigational MC4R agonists bivamelagon & RM-718, alongside preclinical small molecules for congenital hyperinsulinism.
  • Setmelanotide is contraindicated for patients with benign POMC, PCSK1, or LEPR variants & other obesity types unrelated to the specified genetic or acquired conditions.
  • Important safety warnings include risks of spontaneous penile erections, depression, suicidal ideation, hypersensitivity reactions, skin hyperpigmentation, acute adrenal insufficiency, & sodium imbalance.
  • The most common adverse reactions (incidence ≥20%) include skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, & spontaneous penile erection.
  • Use of IMCIVREE is not recommended during breastfeeding, & therapy should be discontinued upon pregnancy recognition unless benefits outweigh fetal risks.
  • Suspected adverse reactions may be reported to Rhythm Pharmaceuticals or the FDA via phone or online portals.
  • The press release includes forward-looking statements regarding clinical progress, regulatory approvals, & commercial growth that are subject to risks & uncertainties.